TiGenix to participate in key investor conferences in April 2017

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogeneic, or donor-derived, stem cells, today announces that its management will be presenting at the 24th annual BioCentury Future Leaders in the Biotech Industry, New York, USA, and the Alliance for Regenerative Medicine (ARM) 5th Annual Cell and Gene Therapy Investor Day, Boston, USA. Tigenix will also be attending the 10th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands.

  • 24th Annual BioCentury Future Leaders in the Biotech Industry
    Date: Friday 7th April 2017
    Venue: Millennium Broadway Hotel & Conference Center, New York, U.S.
    Presenter: Eduardo Bravo, Chief Executive Officer, Tigenix NV
  • 10th Annual Kempen & Co Life Sciences Conference
    Date: Wednesday 19th April 2017
    Venue: Kempen & Co, Beethovenstraat 300, Amsterdam, The Netherlands
    Attendee: Eduardo Bravo, Chief Executive Officer, Tigenix NV
  • Alliance for Regenerative Medicine (ARM) 5th Annual Cell and Gene Therapy Investor Day
    Date: Thursday 27th April 2017
    Venue: The State Room, 60 State Street, Boston, U.S.
    Presenter: Eduardo Bravo, Chief Executive Officer, Tigenix NV

Note

TiGenix NV (Euronext Brussels and NASDAQ: TIG) is a biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogeneic, or donor-derived, stem cells generated by its proprietary platform technologies.

TiGenix's lead product, Cx601, has successfully completed a European Phase III for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) is expected to start in 2017. TiGenix has entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the U.S. Our second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in Western world hospitals. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?